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Aims In the adult heart, Notch signalling regulates the response to injury. Notch inhibition leads to increased cardiomyo-
cyte apoptosis, and exacerbates the development of cardiac hypertrophy and fibrosis. The role of Notch in the mes-
enchymal stromal cell fraction, which contains cardiac fibroblasts and cardiac precursor cells, is, however, largely
unknown. In the present study, we evaluate, therefore, whether forced activation of the Notch pathway in mesen-
chymal stromal cells regulates pathological cardiac remodelling.
Methods
and results
We generated transgenic mice overexpressing the Notch ligand Jagged1 on the surface of cardiomyocytes to activate
Notch signalling in adjacent myocyte and non-myocyte cells. In neonatal transgenic mice, activated Notch sustained
cardiac precursor and myocyte proliferation after birth, and led to increased numbers of cardiac myocytes in adult
mice. In the adult heart under pressure overload, Notch inhibited the development of cardiomyocyte hypertrophy
and transforming growth factor-b/connective tissue growth factor-mediated cardiac fibrosis. Most importantly,
Notch activation in the stressed adult heart reduced the proliferation of myofibroblasts and stimulated the expansion
of stem cell antigen-1-positive cells, and in particular of Nkx2.5-positive cardiac precursor cells.
Conclusions We conclude that Notch is pivotal in the healing process of the injured heart. Specifically, Notch regulates key cel-
lular mechanisms in the mesenchymal stromal cell population, and thereby controls the balance between fibrotic and
regenerative repair in the adult heart. Altogether, these findings indicate that Notch represents a unique therapeutic
target for inducing regeneration in the adult heart via mobilization of cardiac precursor cells.
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Introduction
In the mammalian heart, a rapid shift from myocyte hyperplasia to
myocyte hypertrophy occurs shortly after birth.1 Therefore, the
heart has been considered a post-mitotic organ with a response
to injury restricted to fibrosis and cardiomyocyte hypertrophy.
However, new myocyte formation takes place in the adult heart
due to the recruitment of pre-existing immature myocytes and
cardiac precursor cells (CPCs).2–4 Resident CPCs have been iden-
tified by the expression of surface markers such as stem cell
antigen-1 (Sca-1) or c-Kit, and co-expression of early cardiac
markers such as Nkx2.5, GATA4, and Mef2c.5 However, the
adult heart has limited regenerative potential. Upon tissue
damage, fibroblast proliferation far exceeds that of CPCs. Conse-
quently, a fibrotic scar is generated instead of a functional myocar-
dium derived from newly formed cardiomyocytes.
The reason why the mammalian heart adopts fibrosis as its
primary repair process remains unknown. One of the key regula-
tors of fibrosis is transforming growth factor (TGF)-b, which
induces myofibroblast differentiation.6 Its downstream target, con-
nective tissue growth factor (CTGF) promotes cardiomyocyte
hypertrophy, enhances fibrosis, and stabilizes the fibrotic scar.7
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Periostin (Postn) is also a TGF-b-inducible matricellular protein
that regulates matrix production and stabilization.8 Together,
these factors orchestrate fibrotic repair after injury. Unfortunately,
the fibrous scar represents a hostile environment, preventing re-
generative processes to take place.9 Experimental evidence indi-
cates that limiting cardiac fibrosis improves function of the
injured heart10–13 and could tip the balance towards regener-
ation.9,14 However, additional cues to induce cardiac precursor
mobilization and myocyte proliferation need to be imposed. Signal-
ling pathways that are important for cardiac morphogenesis during
the foetal life and that are reactivated in the damaged adult heart,
such as the Notch signalling pathway, could be used to promote
CPC expansion.
The Notch pathway mediates signalling between adjacent cells
expressing transmembrane ligands (Jagged1 and 2; Delta-like1, 3,
and 4) and receptors (Notch1–4).15 In the developing heart,
Notch regulates trabeculation, myocyte proliferation, and valve
formation.16 Mutations in components of the Notch pathway
lead to cardiac abnormalities such as ventricular septal defects
and valve malformation.17,18 In the postnatal heart, Notch regulates
cardiac precursor expansion and differentiation.19 Notch is essen-
tial for the maintenance of structural and functional integrity during
the response to increased workload.20–23 This pathway is activated
in cardiac myocytes and mesenchymal precursors secondary to
induced Jagged1 expression,20 and sustains the proliferation of
committed precursors and immature cardiomyocytes.20,24,25
Pharmacological or genetic blockade of the Notch pathway
exacerbates hypertrophy, and leads to the development of
massive fibrosis.20
Altogether, these findings suggest that activation of the Notch
pathway enhances myocyte production after damage. We have
generated, therefore, transgenic mice overexpressing Jagged1 on
the surface of cardiomyocytes to chronically activate Notch in ad-
jacent myocytes and mesenchymal stromal cells such as fibroblasts
and cardiac precursors, and evaluated the cardiac response to
pressure overload. We show that Notch activation restrains
cardiac hypertrophy and fibrosis, and promotes cardiac precursor
expansion. Therefore, Notch could be used to shift the response
to injury in the adult mammalian heart towards regeneration.
Methods
All methods are available in Supplementary material online.
Results
Enhanced Notch activation in transgenic
mice with cardiac-specific Jagged1
overexpression
Since adult cardiac precursor-specific markers are currently
lacking, Notch signalling restricted to this lineage cannot be
easily achieved in transgenic animals. To activate Notch in the
adult myocyte and non-myocyte cells, we generated
NMRI-Tg(Myh6::Jagged1)89Ped mice expressing Jagged1 under
control of the a-myosin heavy chain (a-MHC) promoter
(hereafter referred to as TGJ1 mice). Litters derived from hetero-
zygote breeding contain 40–45% transgenic mice. This is some-
what lower than the expected Mendelian ratio (i.e. 50%),
suggesting that transgene expression produces a slight detrimental
effect during development. RT–PCR analysis showed that adult
transgenic mice expressed more Jagged1 than wild-type (WT) lit-
termates (Supplementary material online, Figure S1A). Overexpres-
sion was already observed 1 week after birth, and peaks in adult
hearts (Supplementary material online, Figure S1B). The myc-tagged
Jagged1 protein was readily detected in the heart, but not in the
skeletal muscle (Figure 1A). In the adult myocardium, Jagged1 was
uniformly expressed on the surface of cardiomyocytes
(Figure 1B), but not in interstitial non-myocyte cells (Supplemen-
tary material online, Figure S1C). Immunostaining using an antibody
against the activated form of Notch1 (Notch1 intracellular domain;
N1IC) showed that the Notch1 pathway was activated in
a-actinin-positive cardiomyocytes and in small interstitial
a-actinin-negative non-myocyte cells (Figure 1C). In transgenics,
the percentage of N1IC-positive cells increased two-fold relative
to WT, indicating that Jagged1 resulted in a sustained activation
of the Notch1 pathway. Echocardiography and histological analysis
revealed an enlargement of the right ventricle (RV) in adult TGJ1
mice (Figure 1D). The RV weight was also heavier in the TGJ1
mice than in control littermates (Supplementary material online,
Figure S2). Interestingly, both the left ventricle (LV) and the RV
had an increased number of cardiomyocytes across the full wall
thickness in transgenic mice (Figure 1F). Cardiac function as
assessed by echocardiography was normal (Supplementary mater-
ial online, Table S1).
Sustained myocyte proliferation in the
neonatal heart of the TGJ1 mice
To determine whether the increased number of myocytes
observed in transgenic hearts resulted from sustained postnatal
proliferation, we determined the number of mitotic phospho-
histone H3 (PH3)-positive cardiac cells in 1 and 2 week-old
mice (Figure 2A). The hearts of 1 week-old TGJ1 mice contained
twice as many PH3-positive cells than WT. This finding was con-
firmed by Ki67 and Cyclin D1 staining (Supplementary material
online, Figure S3A and B). Quantitative RT–PCR also showed
that the G2/M cyclin B1 was more expressed in the TGJ1 mice
(2.5-fold increase; P, 0.05; not shown). Importantly, these differ-
ences disappeared in 2 week-old animals (Figure 2A). To determine
whether proliferating cardiac cells contributed significantly to car-
diomyocyte production, mice were injected with BrdU at 1 week
of age, followed by a 3-week chase period. Under these conditions,
rapidly dividing cells quickly lose BrdU through successive cell divi-
sions. Only cardiomyocytes reaching terminal differentiation
shortly after BrdU administration and slowly dividing cells such
as cardiac stem cells retain BrdU (label retaining cells). In WT
and transgenic mice, BrdU incorporation was detected in cardiac
myocytes (a-actinin-positive cells) and non-myocyte cells
(a-actinin-negative cells; Figure 2B). Quantitative analysis showed
that the number of BrdU-positive myocytes and non-myocytes
was significantly increased in the TGJ1 mice (Figure 2B). Further-
more, the number of BrdU-positive Nkx2.5-positive cells was
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also increased in TGJ1 hearts (Figure 2C). Nkx2.5-positive cells
represented 26+ 4.0 and 45+ 6.6% of total BrdU-positive cells
in WT and in TGJ1 hearts, respectively. It is noteworthy that
cardiac tissues in neonatal transgenic mice presented a less orga-
nized structure than WT (Figure 2B and C ). Taken together,
these data suggested that postnatal Notch activation promoted
cardiomyocyte proliferation and expansion of a cardiac precursor
pool that contributed to the higher cellularity seen in adult trans-
genic hearts.
Attenuated cardiomyocyte hypertrophy
in response to pressure overload in the
TGJ1 mice
Mice were subjected to transaortic constriction (TAC) to produce
pressure overload in the LV. Aortic velocity after TAC was identi-
cal in WT and in TGJ1 hearts (Supplementary material online,
Figure S4A), indicating that the heart was subjected to a comparable
load in both genotypes. Transaortic constriction activated Notch1
Figure 1 Characterization of the TGJ1 mice. (A) Western blot analysis of Jagged1 expression in the heart (H), and skeletal muscle (Sk) of
TGJ1 and wild-type mice using antibodies against myc-tag and Jagged1. (B) Jagged1 (red) expression in cardiomyocytes identified by
a-actinin immunostaining (purple) and laminin (green). DAPI (blue). (C) Notch1 activation detected with antibodies against activated
Notch1 (N1IC; green); a-actinin (red). Bar graph shows the percentage of N1IC-positive nuclei (mean+ SEM; *P, 0.05, five mice per
group). (D) H/E staining of heart sections and short-axis echocardiography images showing enlarged right ventricles in TGJ1 mice (LV, left ven-
tricle; RV, right ventricle; S, septum). (E) Right ventricle wall thickness and diameter in TGJ1 and wild-type mice (mean+ SEM; *P, 0.05, six
mice per group). (F) Laminin immunostaining (green) across full thicknesses of left ventricular and right ventricular of wild-type and TG J1 mice
(right panel). Bar graph shows the number of cells in the left ventricular and right ventricular walls (mean+ SEM; *P, 0.05, three mice per
group). Scale bar in (B) and (C): 50 mm; (D) 1 mm; (F) 100 mm.
M. Nemir et al.2176
in WT and TGJ1 mice, but activation was more important in TGJ1,
as judged by the increased number of N1IC-positive cells (Figure 3A
and F ). Notch2 was moderately stimulated (Figure 3A). The
echocardiographic assessment of cardiac dimensions and function
demonstrated the development of hypertrophy in WT controls
after TAC (Supplementary material online, Table S1). The cross-
sectional area of WT cardiomyocytes was increased in response
to stress, and the size distribution shifted towards larger cells
(Figure 3B–D). As a consequence, LV weight was heavier in
WT mice subjected to pressure overload than in sham-operated
animals (Figure 3E). Markers of cardiac hypertrophy were
up-regulated in the stressed WT hearts (Figure 3F). In sharp
contrast to WT, the hypertrophic response in the TGJ1 mice
was largely reduced (Figure 3 and Supplementary material online,
Table S1, Figure S4B), suggesting that Jagged1-induced activation
of the Notch pathway exerted anti-hypertrophic actions.
Figure 2 Proliferation in the postnatal heart. (A) Number of proliferating cells in the heart of 1 and 2-week-old wild-type and TGJ1
mice. Heart sections stained with antibodies against phosphohistone-H3 (pink) and DAPI (blue). The quantification of PH3-positive cells
(mean+ SEM; *P, 0.05, six mice per group). (B) The identification of proliferating cells in postnatal wild-type and TGJ1 hearts. Mice
received BrdU at p7 and were analysed for BrdU incorporation 3 weeks thereafter. Immunostaining: BrdU (red), a-actinin (green);
laminin (brown); DAPI (blue). Large arrows: cardiomyocytes; small arrows: non-myocyte cells. (C) The identification of
Nkx2.5-proliferating cells in postnatal wild-type and TGJ1 hearts. Immunostaining: BrdU (red), Nkx2-5 (green); laminin (brown); DAPI
(blue). BrdU was detected in Nkx2-5-positive cardiomyocytes (large arrows) and in non-myocytes (small arrows). The quantification
of BrdU-positive cells per mm2 (mean+ SEM; *P, 0.05; four to six mice per group). Scale bar in (A) 50 mm; (B) 10 mm; (C)
50 mm in the single channel micrographs and 10 mm in the merged images.
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The phosphoinositide 3-kinase (PI3K)/Akt pathway regulates cell
growth and the development of cardiac hypertrophy through acti-
vation of the mammalian target of rapamycin (mTOR). Western
blot analysis revealed that TAC induced phosphorylation of Akt,
mTOR, and the effector proteins S6 and 4E-BP1 in the WT mice
(Figure 4A and B). In contrast, the Akt pathway was only minimally
activated after TAC in the TGJ1 mice (Figure 4A and B). The PI3K/
Akt pathway is negatively regulated by the phosphatase and tensin
homolog (PTEN), which is inactivated by phosphorylation. Phos-
phatase and tensin homolog was phosphorylated after TAC in
WT but not in the TGJ1 mice, indicating that active PTEN likely
contributed to the down-regulation of the Akt pathway. The Akt
pathway also promotes cell survival. Despite down-regulation of
the Akt pathway, apoptotic cell death was identical to WT in
TGJ1 mouse hearts, suggesting that transgenic hearts did not dem-
onstrate higher susceptibility to stress (Figure 4C).
Reduced cardiac fibrosis in response to
pressure overload in the TGJ1 mice
The development of fibrosis is under control of soluble factors
such as TGF-b, CTGF, and Postn. We found that the expression
Figure 3 The cardiac hypertrophic response to pressure overload. Wild-type and TGJ1 mice were subjected to transaortic constriction and
analysed after 1 week. (A) The percentage of cardiac cells demonstrating Notch1 (left) or Notch2 (right) activation after transaortic constric-
tion. (B) Heart sections stained with antibodies against laminin (green). (C ) Cardiomyocyte size distribution. (D) Cardiomyocyte cross-sectional
area (mean+ SEM). (E) Post-mortem left ventricular weight in wild-type and TGJ1 mice. (F) Notch target gene expression using qRT–PCR
(upper panel) and cardiac hypertrophy marker expression (lower panel) in wild-type and TGJ1 hearts. Data are expressed as fold change rela-
tive to wild-type Sham. Data in (A), (D), (E), and (F) are presented as mean+ SEM (*P, 0.05 in transaortic constriction vs. Sham; †P, 0.05 in
TGJ1 vs. wild-type; six mice per group). In (C) and (D), values are obtained from at least 700 cells per group. Scale bar in (B) 50 mm.
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of TGF-b1, TGF-b2, CTGF, and Postn was induced by TAC in the
WT mice (Figure 5A). In the TGJ1 mice, however, the induction of
TGF-b2, CTGF and Postn was significantly lower. The expression
of the extracellular matrix proteins collagen I, collagen III, and
fibronectin-1 and of fibroblast-specific protein-1 (Fsp-1) was also
significantly reduced. Transforming growth factor-b2 and CTGF
were expressed by fibroblasts and cardiomyocytes, respectively,
and these factors were up-regulated after TAC in WT, but not
in the transgenic mice (Figure 5B and C). Finally, the quantification
of collagen deposition showed that the TGJ1 mice accumulated sig-
nificantly less interstitial fibrosis when compared with the WT
mice (Figure 5D and E).
Cardiac hypertrophy and fibrosis in
mice lacking Jagged1 expression in
cardiomyocytes
To further study the importance of Jagged1 on cardiac remodelling,
we generated mice with cardiomyocyte-specific Jagged1 deletion
(Jagged1Del/Del) by crossing mice carrying floxed Jagged1 alleles
(B6; 129-Jagged1tmLoxPRad) with a-MHC-MerCreMer mice [B6-
Tg(Myh6-Cre/Esr1*)1Jmk/J005657] expressing a Tamoxifen-inducible
form of the Cre recombinase in cardiomyocytes. Tamoxifen-
induced Jagged1 deletion was confirmed by PCR on cardiac
genomic DNA and by immunostaining (not shown).
Figure 4 Activation of the Akt pathway. (A) Western blot analysis of phosphorylated (P) and total (Tot) PTEN, Akt, mTOR, S6, and 4E-BP1 in
wild-type and TGJ1 mice 1 week after transaortic constriction. (B) Quantitative data are presented as mean+ SEM; six samples per group
(*P, 0.05 in transaortic constriction vs. Sham; †P, 0.05 in TGJ1 vs. wild-type). (C) TUNEL staining (green) in wild-type and TGJ1 hearts
after transaortic constriction; laminin (red), a-actinin (brown). Bar graph: mean+ SEM of TUNEL-positive nuclei per heart section
(*P, 0.05 in transaortic constriction vs. Sham; n ¼ 6 animals per group). Scale bars in (C ) 50 mm.
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Cardiomyocyte-specific Jagged1 knockouts were subjected to
TAC, and analysed 1 and 4 weeks after surgery. No difference in
the hypertrophic response to stress was observed between the
two genotypes after 1 week (Supplementary material online,
Figure S5). Of note, no compensatory expression of other Notch
ligands was observed in the Jagged1Del/Del mice (Supplementary
material online, Figure S6). After 4 weeks, mice lacking Jagged1
demonstrated a modest increase in susceptibility for hypertrophy
after TAC, as judged by the increased expression of cardiac
stress markers (Supplementary material online, Figure S5D). The
development of fibrosis was not affected by the deletion of
Jagged1 in cardiomyocytes.
Notch1 expression in cardiomyocytes is
dispensable for Jagged1-induced
anti-hypertrophic and anti-fibrotic
responses
To evaluate the implication of Notch1 in the anti-hypertrophic and
anti-fibrotic effects of Jagged1, we generated TGJ1 mice lacking
Figure 5 Cardiac fibrosis. (A) Quantitative RT–PCR analysis of fibrosis marker genes in wild-type and TGJ1 mice 1 week after transaortic
constriction. Data are expressed as fold change relative to wild-type Sham (mean+ SEM; n ¼ 6–9 mice per group; *P, 0.05 in transaortic
constriction vs. Sham and †P, 0.05 in TGJ1 vs. wild-type). (B) Transforming growth factor-b2 expression (green) in wild-type and TGJ1
heart sections; laminin (red), DAPI (blue). (C) connective tissue growth factor expression (green) in wild-type and TGJ1 heart sections;
a-actinin (magenta), DAPI (blue). (D) Masson Trichrome staining (blue) in wild-type and TGJ1 heart sections. (E) The per cent fibrotic area
in wild-type and TGJ1 heart sections represented as mean+ SEM (*P, 0.05 in transaortic constriction vs. Sham; †P, 0.05 in TGJ1-transaortic
constriction vs. wild-type-transaortic constriction; transaortic constriction, n ¼ 6, Sham, n ¼ 4). Scale bars in (B) and (C) 50 mm; in D ¼ 1.0 mm
and 0.5 mm in higher magnification insets.
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Notch1 in cardiomyocytes by crossing TGJ1 mice to floxed
Notch1 mice (B6;129-Notch1tmLoxPRad) and a-MHC-MerCreMer
mice. Tamoxifen was injected to adult mice to delete Notch1 in
cardiomyocytes (Notch1Del/Del mice). When subjected to TAC,
WT; Notch1Lox/Lox mice (WT controls) developed a hypertrophic
response, characterized by an increase in the LV mass (Supplemen-
tary material online, Figure S7 and Table S2). In the TGJ1 mice with
or without Notch1 deletion, the hypertrophic response was
absent or limited. The deletion of Notch1 was not compensated
by up-regulation of other Notch receptors (Supplementary mater-
ial online, Figure S7B). In addition, pressure overload induced
Notch2 expression and activation but this induction was abrogated
after the deletion of Notch1 (Supplementary material online,
Figures S7B and C), indicating that activation and expression of
Notch2 did not compensate for the lack of Notch1, and that
Notch1 expression in cardiomyocytes is necessary for Notch2 ac-
tivation and expression.
Enhanced Notch activation favours the
expansion of cardiogenic precursors and
inhibits myofibroblast proliferation in the
adult heart
The cell surface antigen Sca-1 has been used to identify CPCs in
the heart. Sca-1-positive cells were found as individual cells or as
cell clusters in interstitial spaces. Cells expressing Sca-1 were par-
ticularly present in the sub-epicardial region (Figure 6A). Under
basal conditions, the number of Sca-1-positive cells was not differ-
ent in WT and TGJ1 hearts (Figure 6B and C ). Aortic constriction
did not change the amount of Sca-1-positive cells in WT animals. In
sharp contrast, TAC increased the number of Sca-1-positive cells,
the number of Sca-1-positive cells per cluster, and the number of
Sca-1-positive clusters in TGJ1 mice (Figure 6C). We next purified
the mesenchymal fraction from adult heart, and demonstrated
using cytofluorometry that these cells expressed Sca-1
(Figure 6D). After the induction of differentiation in vitro, cells
up-regulated Nkx2.5 expression, and even differentiated into
a-actinin-positive cardiomyocytes. These data confirmed that
these cells represent true cardiac progenitors. Interestingly, Sca-1-
positive cells were also largely positive for N1IC (Figure 6E), sug-
gesting that the Notch signalling pathway was activated in these
subpopulation. We next determined whether Sca-1-positive cells
expressed the early cardiac marker Nkx2.5 in vivo. Although
Nkx2.5-positive cells can be found within clusters of Sca-1-positive
cells, most of the Nkx2.5-positive cells were Sca-1-negative
(Figure 6E). This finding is consistent with previous observation
demonstrating a down-regulation of Sca-1 expression in cardiac
committed precursors31.
To evaluate whether Jagged1 overexpression stimulated CPC
production in the stressed heart, we quantified the number of pro-
liferating a-actinin-negativeNkx2.5-positive non-myocyte cells. WT
and TGJ1 mice were subjected to TAC and given BrdU throughout
the duration of the experiment. In sham-operated animals, the total
number of BrdU-positive cells was higher in the TGJ1 mice com-
pared with WT, and aortic constriction increased the number of
BrdU-positive cells both inWTand TGJ1 hearts (Figure 7B). To iden-
tify proliferating cells, heart tissues were further analysed for
a-smooth muscle actin (a-SMA) expression to detect myofibro-
blasts, and for Nkx2.5 expression to identify cardiogenic precursors
and cardiomyocytes. In theWTmice, TAC inducedmassive prolifer-
ation of a-SMA-positive myofibroblasts. In contrast, TAC induced
no proliferation of a-SMA-positive cells in the TGJ1 mice
(Figure 7A and B). We next identified Nkx2.5 expressing cells
(Figure 7C). Nkx2.5 expression was strong in the nuclei of cardio-
myocytes (big arrows) but weaker in non-myocyte cells (small
arrows). The BrdU-positive cells in the TGJ1 mice were essentially
Nkx2.5-positive non-myocyte cells, indicating that transgene ex-
pression resulted in a preferential expansion of cardiac precursor
cells (Figure 7C and D).
We next quantified Nkx2.5-positive myocytes and non-myocyte
cells in the hearts of WT and TGJ1 mice (Figure 8). Nkx2.5-positive
cardiac myocytes in transgenic hearts were characterized by a
smaller size compared with WT, consistent with an immature
phenotype (Figure 8A and B). Precursor cells were observed as
clusters of Nkx2.5-positive non-myocyte cells in interstitial
spaces. The total number of Nkx2.5-positive cells was increased
in the TGJ1 mice, due to higher amounts of Nkx2.5-positive pre-
cursor cells (Figure 8Ca, c, and e). After TAC, the number of pre-
cursors in WT mice reached levels measured in TGJ1 animals
(Figure 8Cc). The Nkx2.5-positive cardiomyocyte population was
also larger in the transgenic mice after TAC than in WT
(Figure 8Ce). We next identified cells with an activated Notch1 sig-
nalling pathway (N1IC-positive cells) (Figure 8Cb, d, and f ). In the
TGJ1 mice, the number of Nkx2.5-positive cardiomyocytes with
an activated Notch1 pathway was increased under basal conditions
and after TAC when compared with WT (Figure 8Cf ). In contrast,
Nkx2.5-positive CPCs in sham-operated TGJ1 were essentially
N1IC-negative (Figure 8Cd).
Discussion
New cardiomyocytes are produced in the adult heart after injury,
and cardiac stem cells contribute to myocyte renewal.4 However,
the molecular mechanisms that could force the heart to adopt re-
generation as a default pathway have not been identified. In the
present study, we show that the Jagged1 expression on the
surface of cardiomyocytes promotes the expansion of
Nkx2.5-positive cardiac precursors and immature cardiomyocytes,
which ultimately produce differentiated cardiomyocytes. In the
adult heart, the amount of cells expressing Sca-1 (CPCs) is
increased when Notch signalling is activated. A significant
number of clusters containing Sca-1-positive cells contain also
Nkx2.5-positive cells. However, Sca-1-positive cells are essentially
Nkx2.5-negative. This is consistent with previous observation sug-
gesting that cardiac committed CPCs down-regulate Sca-1 expres-
sion.31 In addition, Notch activation, primarily via its actions on the
fibroblast population, prevents pro-hypertrophic and pro-fibrotic
factor production and limits cardiac hypertrophy and fibrosis in re-
sponse to pressure overload. The effects of Notch on the cardiac
microenvironment create favourable conditions for the production
of cardiac precursors, and improve the capacity of the adult heart
to respond to damage.
In WT animals, pressure overload induces cardiomyocyte hyper-
trophy. In contrast, TGJ1 mice, Notch activation limits myocyte
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hypertrophy in response to stress. This is consistent with previous
data showing that the pharmacological or genetic blockade of
Notch1 exacerbates the development of cardiac hypertrophy.20
In the TGJ1 mice, Notch could suppress GATA-dependent gene
transcription of sarcomeric proteins, possibly via Hes and Hey pro-
teins.32 Indeed, cardiac gene expression is lower in transgenic
hearts when compared with WT. Nevertheless, this might reflect
more an improved adaptation to stress than an actual cause for
the absence of growth. The PI3K/Akt pathway is down-regulated
in the heart of the TGJ1 mice. Increased activation of the Akt
pathway can have detrimental and beneficial effects on heart func-
tion.33 Sustained Akt signalling leads to hypertrophy and failure. On
the other hand, activated Akt confers protection via the activation
of survival pathways. Forced expression of N1IC or delivery of
Figure 6 Increased number of Sca-1-positive cells in the stressed TGJ1 heart. (A) Sca-1 expression (red) in TGJ1 heart sections identifying
Sca-1-positive cells as single cells or multiple cell clusters; DAPI (blue). Epicardial region (epi). (B) Sca-1 expression (red) in wild-type and TGJ1
heart sections after transaortic constriction. (C) Quantification: total number of Sca-1-positive cells per mm2 (left); number of Sca-1-positive
cells per cluster (middle); number of Sca-1-positive clusters per mm2 (right), in wild-type and TGJ1 mice after transaortic constriction.
(mean+ SEM; *P, 0.05 in transaortic constriction vs. Sham; †P, 0.05 in TGJ1 vs. wild-type; n ¼ 4–6 mice per group). (D) Upper panels:
cytofuorometry analysis of Sca-1 expression in cardiac non-myocyte cells from adult wild-type and TGJ1 mouse hearts (blue: negative
control antibody; red: anti-Sca-1 antibody); lower panels: cultured cardiac non-myocytes maintained in differentiation medium for 2 weeks.
Cells were stained with antibodies against Sca-1 (red), Nkx2.5 (green), and a-actinin (grey); DAPI (blue). (E) Upper panels: activated
Notch1 in Sca-1-positive a-actinin-negative cells (N1IC: green; Sca-1: red; a-actinin: white; DAPI: blue); lower panels: Sca-1-positive
a-actinin-negative cells are Nkx2.5-negative (Nkx2.5: green; Sca-1: red; a-actinin: white; DAPI: blue). Scale bar in (A) (left): 20 mm; in (A)
(right): 50 mm, in (B): 50 mm; in (D) 50 mm, and in (E) 10 mm.
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Notch1 pseudoligand increase myocyte survival via Akt.21,22 The
fact that the number of apoptotic cells is similar in WT and
TGJ1 mice indicates that the lack of Akt activation in TGJ1
hearts does not affect cardiomyocyte survival. Therefore, the
transgenic heart must rely on different cellular mechanisms to
improve its response to stress. Several reports have demonstrated
a crucial role of Notch in stem cell expansion and survival.16,34
Here, we show that transgenic hearts contain more cardiomyo-
cytes and cardiac precursors, which, respectively, constitute add-
itional functional reserve to cope with work overload, and a
larger cardiac precursor pool with increased capacity to replenish
lost cardiomyocytes.
Forced expression of N1IC in cardiomyocytes during develop-
ment impairs cardiogenic differentiation and produces myocyte
hyperplasia.22,35 Notch activates also cell-cycle re-entry in imma-
ture cardiomyocytes.24,25 Based on the myocyte size, persistent
postnatal proliferation and a less organized cardiac tissue, neonatal
TGJ1 hearts present a rather immature phenotype compared with
WT. Hyperplasia occurs in both ventricles but is particularly pro-
nounced on the right side, consistent with previous findings dem-
onstrating a preferential role for Notch in cardiac structures
derived from the secondary heart field.36 In immature cardiomyo-
cytes, the expression of components of the Notch pathway grad-
ually declines after birth,25 likely contributing to the progression of
Figure 7 Jagged1-mediated cardiac precursor expansion. Mice were subjected to transaortic constriction and given BrdU for 2 weeks. (A)
a-smooth muscle actin expression (green) and BrdU incorporation (red) in wild-type and TGJ1 heart sections; DAPI (blue). (B) Quantification:
numbers of BrdU-positive and BrdU- and a-smooth muscle actin-positive cells in heart sections. (C) Nkx2.5 expression (green) and BrdU in-
corporation (red) in wild-type and TGJ1 heart sections; DAPI (blue). Large arrows indicate cardiomyocytes and small arrows indicate
Nkx2-5-positive non-myocyte cells. (D) Quantification: numbers of BrdU-positive and BrdU- and Nkx2.5-positive cells in heart sections. Bar
graphs represent mean+ SEM (*P, 0.05 in transaortic constriction vs. Sham; †P, 0.05 in TGJ1 vs. wild-type; n ¼ 6 mice per group). Scale
bars in (A) 50 mm; in (C) 20 mm.
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cardiomyocytes into a fully differentiated post-mitotic state. Like-
wise, embryonic and cardiac stem cells lacking RBP/Jk or Notch1
expression possess an increased capacity to differentiate into car-
diomyocytes.20,37,38 Therefore, by repressing cardiac gene expres-
sion and limiting the production of organized sarcomeres, Notch
could maintain cardiomyocytes in an immature state that renders
cytokinesis achievable.39 In the TGJ1 mice, we observed increased
PH3 and Ki67 staining and an up-regulation of cyclins B1 and D1
expression in the neonatal transgenic heart, indicating that cells
advance into the G2/M phases. Cyclins and cyclin-dependent
kinase inhibitors have been shown to be targets of Notch signal-
ling.24 Consistent with these findings, inhibition of Notch using
g-secretase inhibitor administration in neonatal mice results in a
reduction of number of cardiomyocytes and dilated cardiomyop-
athy.19 Therefore, the Notch pathway exerts combined actions
in the myocyte lineage, which result in a sustained proliferation
in the postnatal myocyte population.
The development of cardiac hypertrophy and fibrosis reflects
cellular responses to autocrine and paracrine growth factors.
Transforming growth factor-b and CTGF, together with other
factors such as Postn, regulate myocyte growth as well as myofi-
broblast proliferation and differentiation after injury.6,7,10 A major
finding in the current study is that TGF-b2, CTGF, and Postn are
down-regulated by Jagged1-induced Notch signalling in the heart.
Figure 8 Jagged1-mediated Nkx2.5-positive cardiac myocyte and precursor expansion. (A) Nkx2.5 (pink) and laminin expression (green), and
N1IC staining (white) in wild-type and TGJ1 heart sections; DAPI (blue). (B) High magnification photomicrographs of TGJ1 heart section after
transaortic constriction. Large arrows indicate immature Nkx2.5- and N1IC-positive cardiomyocytes, and small arrows indicate Nkx2.5-positive
non-myocyte cells. (C) Quantification: numbers of Nkx2.5-positive cells in heart sections. (a and b) Total numbers; (c and d), precursors, (e and
f ), cardiomyocytes. Bar graphs represent mean+ SEM. mm2 (*P, 0.05 in TGJ1 vs. wild-type; †P, 0.05 in transaortic constriction vs. Sham;
n ¼ 4–6 mice per group, five fields per heart). Scale bar in (A) 50 mm; in (B) 20 mm.
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Cross-talk between Notch and TGF-b pathways are crucial during
the development of the heart, and has been described to regulate
fibrosis in several organs in the adult.36,40 In the TGJ1 mice, there-
fore, blunted factor expression prevents cardiomyocyte growth
and fibroblast differentiation. Neutralization of TGF-b appears to
affect primarily interstitial non-myocyte cells, and suppresses fibro-
sis induced by pressure overload.10 Interestingly, TGF-b2 enhances
cardiogenic differentiation in embryonic stem cells.41 Therefore,
reduced TGF-b2 signalling might also contribute to prevent pre-
mature differentiation in cardiac precursors and favour expansion.
Connective tissue growth factor has been shown to induce cardi-
omyocyte hypertrophy through the activation of the Akt
pathway.42,43 The down-regulation of CTGF expression and of
the Akt pathway explains in part the absence of a hypertrophic re-
sponse in the TGJ1 mice. Finally, cardiac Postn expression was also
abolished in the TGJ1 mice, probably secondary to reduced
TGF-b2 production.8 Periostin does not affect the number of
cardiac fibroblasts but enhances their profibrogenic capacity.
Mice lacking Postn exhibit less cardiac fibrosis under pressure
overload.12 Periostin was claimed to induce myocyte cytokinesis
but this finding has not been confirmed.44,45 Since the TGJ1
mice demonstrate low Postn levels but still increased numbers of
cardiac precursors and myocytes, a major role for Postn in stimu-
lating proliferation in the cardiogenic lineage is not supported by
our study.
Notch1 deletion specifically in cardiomyocytes does not alter
the phenotype of the TGJ1 mice. Since increased Notch2 signalling
is not observed in the stressed transgenic heart, it is unlikely that
compensatory Notch2 signalling takes place in the myocyte
population. Therefore, the cardiac mesenchymal fraction must
represent the prime target of Notch1 signalling and a main integra-
tor of stress during the response to injury. Resident cardiac fibro-
blasts originate from embryonic stromal cells. However, cardiac
fibroblasts can also be generated from endothelial cells via
endothelial-to-mesenchymal transition,46 from the epicardium via
epithelial-to-mesenchymal transition8 or from the bone-marrow.47
Likewise, cardiac stem cells share characteristics of mesenchymal
stem cells (or mesenchymal stromal cells), and derive from
similar cellular compartments in the heart.23,31,48–50 Generation
of either fibroblasts or cardiac precursors could, therefore, be
regulated by common mechanisms. Depending on the microenvir-
onment, reactivation of developmental pathways as well as auto-
crine and paracrine factors modulate the response towards
resident cardiac precursor mobilization or fibroblast produc-
tion.9,14 Recently, a Notch-activated epicardium-derived cell popu-
lation was shown to contribute to tissue repair in the heart.23
These cells have characteristics of mesenchymal stem cells, and
demonstrate fibrogenic and cardiogenic potential. Upon cardiac
injury, fibrosis genes are up-regulated and muscle genes down-
regulated, suggesting again that fibrogenesis represents a default
pathway in the damaged myocardium. Along these lines, CTGF
was recently shown to induce differentiation of multipotent mes-
enchymal stem cells into a-SMA-positive myofibroblasts.51
However, our results demonstrate that, in the absence of addition-
al profibrotic cues such as TGF-b, CTGF, and Postn signalling,
Notch-activated cells preferentially contribute to the cardiogenic
lineage. Interestingly, down-regulation of Notch signalling in
cardiac fibroblasts is necessary for their transformation into
a-SMA-positive myofibroblasts.52 We conclude, therefore, that
communication between Jagged1-expressing cardiomyocytes and
Notch-expressing mesenchymal cells is crucial to shift the
response towards cardiac precursor expansion. It remains that
cross-talk between myocytes and non-myocyte cells is bidirection-
al. For example, Jagged1 on the surface of mesenchymal stem cells
activates Notch in adjacent cardiomyocytes, and, together with
secreted factors, promotes the proliferation of immature myo-
cytes.53 These additional signalling events could compensate for
any disrupted communication in cardiomyocyte-specific Jagged1
knockouts.
In summary, we propose that Notch is pivotal in a
complex network of interactions between cardiomyocytes and
mesenchymal cells. Through regulating fibrogenesis and cardiogen-
esis, Notch is able to switch the cardiac repair mechanisms from a
profibrotic default pathway to a pro-cardiogenic pathway. Al-
together, our results suggest that the Notch pathway represents
a unique therapeutic target that can be manipulated to improve
the cardiac response to stress and regenerate the damaged myo-
cardium via mobilization of cardiac precursor cells.
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